drugset / Trial / NCT02685345

A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin

NCT02685345

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of the study is to evaluate the efficacy and safety of DS-8500a compared with placebo in patients with type 2 diabetes mellitus (T2DM) receiving sitagliptin.

Timeline

Start
2016-01
Primary completion
2016-09
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject FIRUGLIPEL Small molecule 25 mg Oral
Subject FIRUGLIPEL Small molecule 75 mg Oral